ZA201804227B - Methods of treating cancer - Google Patents

Methods of treating cancer

Info

Publication number
ZA201804227B
ZA201804227B ZA2018/04227A ZA201804227A ZA201804227B ZA 201804227 B ZA201804227 B ZA 201804227B ZA 2018/04227 A ZA2018/04227 A ZA 2018/04227A ZA 201804227 A ZA201804227 A ZA 201804227A ZA 201804227 B ZA201804227 B ZA 201804227B
Authority
ZA
South Africa
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
ZA2018/04227A
Other languages
English (en)
Inventor
Willingham Stephen
A Miller Richard
Y Ho Po
Mccaffery Ian
Hotson Andrew
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of ZA201804227B publication Critical patent/ZA201804227B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2018/04227A 2015-12-24 2018-06-22 Methods of treating cancer ZA201804227B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562387383P 2015-12-24 2015-12-24
US201662324211P 2016-04-18 2016-04-18
US201662350602P 2016-06-15 2016-06-15
US201662421109P 2016-11-11 2016-11-11
US201662421171P 2016-11-11 2016-11-11
PCT/US2016/068459 WO2017112917A1 (en) 2015-12-24 2016-12-22 Methods of treating cancer

Publications (1)

Publication Number Publication Date
ZA201804227B true ZA201804227B (en) 2022-07-27

Family

ID=59091273

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/04227A ZA201804227B (en) 2015-12-24 2018-06-22 Methods of treating cancer

Country Status (13)

Country Link
US (2) US10912776B2 (enExample)
EP (1) EP3393475B1 (enExample)
JP (1) JP6847958B2 (enExample)
KR (1) KR20180103918A (enExample)
CN (1) CN108883107A (enExample)
AU (1) AU2016379425B2 (enExample)
CA (1) CA3009527C (enExample)
EA (1) EA201891509A1 (enExample)
ES (1) ES3017686T3 (enExample)
IL (1) IL260199B (enExample)
MX (1) MX391382B (enExample)
WO (1) WO2017112917A1 (enExample)
ZA (1) ZA201804227B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187484A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
AU2018317390A1 (en) * 2017-08-14 2020-04-02 Cytodigm, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
CN109662966A (zh) * 2017-10-16 2019-04-23 北京莱科金基因科技有限责任公司 伊曲茶碱在制备用于肿瘤治疗的药物中的用途
EP3706753A4 (en) * 2017-11-06 2021-12-22 Corvus Pharmaceuticals, Inc. ADENOSINE PATHWAY INHIBITORS FOR CANCER TREATMENT
US20200261462A1 (en) * 2017-11-06 2020-08-20 Corvus Pharmaceuticals, Inc. Combination therapy for cancer treatment
EP3520782A3 (en) 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN111615389A (zh) * 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
WO2019233994A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
JOP20200342A1 (ar) 2018-07-05 2020-12-30 Incyte Corp مشتقات بيرازين مدمجة كمثبطات a2a/a2b
KR102767594B1 (ko) 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
WO2020014666A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20200105246A (ko) * 2019-02-28 2020-09-07 한미약품 주식회사 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
CN112608316B (zh) * 2019-07-30 2022-10-21 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类腺苷受体拮抗剂
WO2021105232A1 (en) * 2019-11-26 2021-06-03 Astrazeneca Ab Methods of treating cancer
WO2021119193A2 (en) * 2019-12-09 2021-06-17 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
PH12022551639A1 (en) * 2020-01-03 2024-02-12 Incyte Corp Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
CA3206018A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN116898858B (zh) * 2023-08-11 2025-09-23 锦州医科大学 一种治疗非小细胞肺癌的药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
RU2711380C2 (ru) 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187484A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3706753A4 (en) * 2017-11-06 2021-12-22 Corvus Pharmaceuticals, Inc. ADENOSINE PATHWAY INHIBITORS FOR CANCER TREATMENT
CN111615389A (zh) * 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物

Also Published As

Publication number Publication date
KR20180103918A (ko) 2018-09-19
US10912776B2 (en) 2021-02-09
EP3393475C0 (en) 2025-02-05
US12023337B2 (en) 2024-07-02
US20190076433A1 (en) 2019-03-14
US20210154199A1 (en) 2021-05-27
IL260199A (en) 2018-07-31
JP6847958B2 (ja) 2021-03-24
CN108883107A (zh) 2018-11-23
CA3009527C (en) 2024-01-09
WO2017112917A8 (en) 2018-07-26
EP3393475A1 (en) 2018-10-31
MX391382B (es) 2025-03-21
AU2016379425B2 (en) 2021-11-11
EP3393475B1 (en) 2025-02-05
CA3009527A1 (en) 2017-06-29
EA201891509A1 (ru) 2019-01-31
JP2019503365A (ja) 2019-02-07
IL260199B (en) 2022-01-01
AU2016379425A1 (en) 2018-07-12
EP3393475A4 (en) 2019-08-14
ES3017686T3 (en) 2025-05-13
WO2017112917A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
IL259783A (en) Methods of treatment of malignant diseases
SG10202110594UA (en) Methods of treating tumor
SG10201801562PA (en) Combination method for treatment of cancer
IL259996A (en) Combinations for cancer treatment
IL262342A (en) Cancer treatment methods
IL256836B (en) Methods for treating cancer using apilimod
IL263508A (en) Methods of treating pancreatic cancer
IL255022A0 (en) Cancer treatment methods
EP3119390A4 (en) Methods of treating cancer
IL263835A (en) Exosome-guided treatment of cancer
IL255018A0 (en) Cancer treatment methods
GB201408297D0 (en) Treatment of cancer
IL255016A0 (en) Cancer treatment methods
IL253847A0 (en) Methods of treating diseases
SG11202005163PA (en) Methods of treating cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
IL269123A (en) Methods of treating cancer
GB201407837D0 (en) Methods of cancer therapy
GB201510197D0 (en) Method of treating ovarian cancer
GB201512139D0 (en) Methods of treatment
GB201417456D0 (en) Treatment of cancer
EP3125878A4 (en) Methods of treating breast cancer